European Penny Stocks To Consider In September 2026

European markets have experienced volatility recently, driven by rising oil and natural gas prices due to escalating Middle East tensions, which has heightened inflation concerns and affected equity performance. Despite these challenges, investors continue to seek opportunities in various market segments, including penny stocks. Although the term "penny stocks" may seem outdated, it remains relevant for those interested in smaller or newer companies that can offer affordability and growth potential when supported by strong financial health.

We'll examine a selection from our screener results.

Olidata (BIT:OLI)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Olidata S.p.A. operates as a technology consulting company with a market cap of €30.47 million.

Operations: The company generates €93.56 million in revenue from its computer hardware segment.

Market Cap: €30.47M

Olidata S.p.A., with a market cap of €30.47 million, is navigating the penny stock landscape with some financial strengths and challenges. It boasts short-term assets of €76.8 million, which exceed its long-term liabilities of €7 million, and has more cash than total debt. However, its short-term liabilities (€92.6M) surpass these assets, indicating liquidity concerns. The company has reduced its debt-to-equity ratio significantly over five years and maintains well-covered interest payments by EBIT (6.5x). Despite this, Olidata's Return on Equity is low at 1.9%, and profit margins have declined to 0.3% from last year's 1%.

• Take a closer look at Olidata's potential here in our financial health report.
• Learn about Olidata's historical performance here.

Cellectis (ENXTPA:ALCLS)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Cellectis S.A. is a clinical stage biotechnological company focused on developing gene-editing products, including allogeneic chimeric antigen receptor T-cells for immuno-oncology and gene therapy candidates for other therapeutic areas, with a market cap of €101.12 million.

Operations: The company generates its revenue primarily from the Therapeutics segment, totaling $63.82 million.

Market Cap: €101.12M

Cellectis, with a market cap of €101.12 million, is undergoing a strategic transformation to focus on in vivo gene editing for chronic diseases, leveraging its extensive gene editing toolbox. Despite recent revenue declines to US$6.9 million from US$18.19 million year-on-year and continued unprofitability with significant losses, the company maintains a strong cash position exceeding its total debt and has sufficient cash runway for over three years based on current free cash flow. The shift away from CAR T-cell therapies aims to maximize resource efficiency and extend financial flexibility into H2 2028 while pursuing promising preclinical programs like .HEAL-101 and .HEAL-201.

• Click to explore a detailed breakdown of our findings in Cellectis' financial health report.
• Gain insights into Cellectis' outlook and expected performance with our report on the company's earnings estimates.

BTCS (WSE:BTF)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: BTCS S.A. operates in the bitcoin and blockchain infrastructure sector in Poland with a market capitalization of PLN66.24 million.

Operations: The company generates revenue primarily from its wholesale segment focused on computer peripherals, amounting to PLN2.91 billion.

Market Cap: PLN66.24M

BTCS S.A., with a market cap of PLN66.24 million, operates in the bitcoin and blockchain sector but remains pre-revenue, generating less than US$1 million. Recent earnings show improved revenue at PLN1.24 million for Q2 2026, up from last year, yet the company is still unprofitable with a net loss of PLN0.34 million for the same period. Despite high volatility and insufficient short-term assets to cover liabilities, BTCS is debt-free and maintains a positive cash flow sufficient for over three years without shareholder dilution in the past year.

• Navigate through the intricacies of BTCS with our comprehensive balance sheet health report here.
• Assess BTCS' previous results with our detailed historical performance reports.

Seize The Opportunity

• Embark on your investment journey to our 308 European Penny Stocks selection here.
• Ready For A Different Approach? AI is about to change healthcare. These 132 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com